Months after a major rebranding around CAR-NKT cells, Kuur Therapeutics is offering a peek at early results

Nicole DeFeudis

Editor

Several months after a name change and major restructuring, Kuur Therapeutics has offered an early glimpse at results from a small number of patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Months after a major rebranding around CAR-NKT cells, Kuur Therapeutics is offering a peek at early results

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Months af­ter a ma­jor re­brand­ing around CAR-NKT cells, Ku­ur Ther­a­peu­tics is of­fer­ing a peek at ear­ly re­sults

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Months after a major rebranding around CAR-NKT cells, Kuur Therapeutics is offering a peek at early results